Investors have reacted enthusiastically to numerous earnings reports by IBD 50 names, sending shares up sharply. Can two more stocks on the elite list that have scheduled Q2 reports maintain the momentum?
It’s been a poor year for growth stocks, but a significant number of solid reports have renewed interest in growth names. The question is can it last?